Cullinan Historical Income Statement
| CGEM Stock | USD 12.54 0.32 2.62% |
Historical analysis of Cullinan Oncology income statement accounts such as Selling General Administrative of 44.6 M, Total Revenue of 0.0 or Cost Of Revenue of 325.5 K can show how well Cullinan Oncology LLC performed in making a profits. Evaluating Cullinan Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cullinan Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cullinan Oncology LLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cullinan Oncology LLC is a good buy for the upcoming year.
Cullinan |
About Cullinan Income Statement Analysis
Cullinan Oncology LLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cullinan Oncology shareholders. The income statement also shows Cullinan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cullinan Oncology Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Cullinan Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Cullinan Oncology's Research Development is very stable compared to the past year. As of the 25th of November 2024, Net Interest Income is likely to grow to about 22.7 M, though Operating Income is likely to grow to (181.5 M).
| 2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology income statement Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Selling General Administrative | 5.5M | 17.1M | 29.1M | 40.2M | 42.5M | 44.6M | |
| Operating Income | (22.3M) | (60.3M) | (68.0M) | 144.6M | (191.1M) | (181.5M) | |
| Net Income From Continuing Ops | (21.7M) | (59.5M) | (65.6M) | 109.2M | (155.1M) | (147.3M) | |
| Ebit | (22.3M) | (60.3M) | (68.0M) | 151.3M | (190.6M) | (181.1M) | |
| Total Operating Expenses | 22.3M | 60.3M | 86.9M | 132.1M | 191.1M | 200.6M | |
| Income Before Tax | (21.7M) | (59.5M) | (67.5M) | 151.3M | (169.2M) | (160.8M) | |
| Total Other Income Expense Net | 616K | 877K | 469K | 6.7M | 21.9M | 23.0M | |
| Net Income Applicable To Common Shares | (20.7M) | (51.8M) | (65.6M) | 111.2M | 127.9M | 134.3M | |
| Net Income | (20.0M) | (50.8M) | (65.0M) | 111.2M | (153.2M) | (145.5M) | |
| Income Tax Expense | (1.6M) | (8.6M) | (2.4M) | 42.1M | (14.1M) | (13.4M) | |
| Research Development | 16.8M | 43.2M | 57.8M | 91.9M | 148.2M | 155.6M | |
| Net Interest Income | 620K | 888K | 477K | 6.6M | 21.6M | 22.7M | |
| Interest Income | 620K | 888K | 477K | 6.6M | 21.6M | 22.7M | |
| Depreciation And Amortization | 70K | 62K | 53K | 93K | 310K | 325.5K | |
| Other Operating Expenses | 22.3M | 60.3M | 86.9M | 132.1M | 191.1M | 200.6M | |
| Ebitda | (22.2M) | (60.3M) | (67.9M) | 151.4M | (190.3M) | (180.8M) | |
| Reconciled Depreciation | 70K | 62K | 53K | 93K | 310K | 325.5K | |
| Minority Interest | 864K | 1.3M | (1.9M) | (2.0M) | 1.9M | 2.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.